# Inimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026

- Source: PR Newswire M&A
- Published: 2026-11-06T15:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/inimmune-presents-late-breaking-phase-1-ini-4001-results-demonstrating-on-target-immune-activation-in-advanced-solid-tumors-at-sitc-2026-302931325.html
- Canonical: https://groundlevelnews.com/story/inimmune-presents-late-breaking-phase-1-ini-4001-results-demonstrating-8d0c81/

Study demonstrated no dose-limiting toxicities and dose-responsive cytokine production consistent with TLR7/8 engagement Results support continued clinical development of INI-4001 as a potential monotherapy and in combination with other cancer treatments MISSOULA, Mont., Nov. 6, 2026...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._